Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 587

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

Open access
Johnson, Nathalie A., Savage, Kerry J., Ludkovski, Olga, Ben-Neriah, Susana, Woods, Ryan, Steidl, Christian, Dyer, Martin J. S., Siebert, Reiner, Kuruvilla, John, Klasa, Richard, Connors, Joseph M., Gascoyne, Randy D., Horsman, Douglas E.·2009·Blood

Abstract

BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2+/MYC+) were identified in 54 samples by karyotype and/or fluorescence in situ hybridization with the aim of correlating clinical and cytogenetic characteristics to overall survival. BCL2+/MYC+ lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1). Despite the presence of a t(14;18), 5 cases were BCL2 protein–negative. Nonimmunoglobulin gene/MYC (non-IG/MYC) translocations occurred in 24 of 54 cases (44%) and were highly associated with DLBCL morphology (P < .001). Over a median follow-up of 5.3 years, 6 patients remained in remission and 32 died within 6 months of the MYC+ rearrangement, irrespective of whether MYC+ occurred at diagnosis (31 of 54) or transformation (23 of 54; P = .53). A non-IG/MYC translocation partner, absent BCL2 protein expression and treatment with rituximab-based chemotherapy, were associated with a more favorable outcome, but a low International Prognostic Index score and DLBCL morphology were independent predictors of overall survival. A comprehensive cytogenetic analysis of BCL2 and MYC status on all aggressive lymphomas may identify a group of high-risk patients who may benefit from chemotherapeutic regimens that include rituximab and/or BCL2-targeted therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-03-212191

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 587

Metadata

Authors
Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M. J. S., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J. M., Gascoyne, R. D., & Horsman, D. E.
Venue
Blood
Published
2009-09-10
Volume
114
Issue
11
Pages
2273-2279
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2153944703
Cited by
587
References
36
FWCI
20.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. https://app.cochat.ai/papers/10.1182/blood-2009-03-212191
The paper
Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M. J. S., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J. M., Gascoyne, R. D., & Horsman, D. E. (2009). Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. https://doi.org/10.1182/blood-2009-03-212191

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.